Notice of extraordinary general meeting and second meeting for liquidation purposes in Enorama Pharma AB (publ)

By Cision
Enorama Pharma

The shareholders of Enorama Pharma AB (publ), reg. no. 556716-5591 (the "Company" or "Enorama Pharma"), are hereby invited to attend an extraordinary general meeting on 4 December 2026 at 10.00 at Advokatfirman Delphi's premises at Skeppsbron 4B in Malmö.

Right to participate and notification

Anyone wishing to attend the general meeting shall:

  1. be registered as a shareholder in the share register prepared by Euroclear Sweden AB as of the record date of 26 November 2026, and
  2. notify the Company of their participation no later than 30 November 2026.

Notification of participation shall be made by email to bolagsstamma@enorama.se. Notification may also be made by post to Enorama Pharma, attn: "Bolagsstämma", Strandvägen 7A, 114 51 Stockholm. The notification should include full name, personal or corporate registration number, shareholding, address, telephone number, email address and, where applicable, information about representatives, proxies or advisers (maximum two).

Proxy and power of attorney

If a shareholder is to be represented by a proxy, the proxy must bring a written and dated power of attorney signed by the shareholder in original to the meeting. The power of attorney may not be older than one year, unless a longer period of validity (but no longer than five years) has been specified in the power of attorney. If the power of attorney is issued by a legal entity, the proxy must also bring a current certificate of registration or equivalent authorisation document for the legal entity. To facilitate admission to the meeting, a copy of the power of attorney and other authorisation documents should be attached to the notification to attend the meeting. Power of attorney forms are available on the Company's website, www.enorama.se, and will be provided by post upon request.

Nominee-registered shares

In order to be entitled to participate in the meeting, a shareholder whose shares are registered in the name of a nominee, through a bank or other nominee, must, in addition to giving notice of attendance at the meeting, have the shares registered in their own name with Euroclear Sweden AB so that the shareholder is entered in the share register as of 26 November 2026. Such re-registration may be temporary (so-called voting rights registration) and is requested from the nominee in accordance with the nominee's routines in such time in advance as the nominee determines. Voting rights registration completed no later than 30 November 2026 will be taken into account when preparing the share register.

Proposal for the agenda

  1. Opening of the meeting
  2. Election of chairman of the meeting
  3. Preparation and approval of the voting list
  4. Approval of the agenda
  5. Election of one or two persons to approve the minutes of the meeting
  6. Determination of whether the meeting has been duly convened
  7. Resolution on introduction of interest under a loan agreement
  8. Presentation of the second balance sheet for liquidation purposes and the auditor's report with respect thereto as well as documents pursuant to Chapter 25, Section 4 of the Companies Act
  9. Resolution on whether the Company should continue its operations or go into liquidation
  10. Closing of the meeting

Proposals for resolutions

Item 2 - Election of chairman of the meeting

The board of directors proposes that Micael Karlsson, attorney-at-law, at Advokatfirman Delphi be appointed chairman of the meeting.

Item 7 - Resolution on introduction of interest under a loan agreement

On 13 November 2026, the Company entered into a loan agreement with DS Global Pte. Limited ("DS Global" or the "Lender") (the "New Loan Agreement"). Under the New Loan Agreement, the Lender makes USD 2,500,000 available to Enorama Pharma. The New Loan Agreement runs up to and including 31 December 2027 and is interest-free. The loan under the New Loan Agreement, including any additional interest, shall be repaid with newly issued shares through a directed share issue to the Lender with payment by way of set-off on the maturity date. The Company is also entitled to repay the loan in cash prior to the maturity date.

DS Global and Enorama Pharma now wish to introduce an annual interest rate of nine (9) percent under the New Loan Agreement. The proposed interest rate is considered to be on market terms. If the extraordinary general meeting resolves to introduce interest under the New Loan Agreement, interest will start to accrue from 4 December 2026.

DS Global, together with companies under common control, holds approximately 29.81 percent of the shares and votes in Enorama Pharma as at the date of this notice. Enorama Pharma is therefore an associate of DS Global. Enorama Pharma and DS Global are thus related parties, and the introduction of interest under the New Loan Agreement shall be regarded as a related party transaction.

Under statement 2019:25 of the Swedish Securities Council (Sw. Aktiemarknadsnämnden), certain related party transactions must be submitted to the general meeting for approval. Transactions requiring approval are those which, together with other transactions carried out with the same related party during the past year, have a value of at least SEK one million (1,000,000) and correspond to at least one (1) percent of the Company's value (calculated as its total market capitalisation).

The board of directors has prepared a report on the transaction in accordance with statement 2019:25 of the Swedish Securities Council, which has been published on the Company's website, www.enorama.se, together with the notice of the general meeting.

A valid resolution requires the support of shareholders representing more than half of the votes cast at the general meeting. Shares and votes held directly or indirectly by DS Global or other companies under common control shall not be taken into account in the resolution of the general meeting.

Item 9 - Resolution on whether the Company should continue its operations or go into liquidation

The Company held an extraordinary general meeting, also serving as the initial meeting for liquidation purposes, on 7 April 2026, at which it was resolved that the Company's operations should continue. Under the Companies Act (2005:551) (Sw. aktiebolagslagen), the Company is required to hold a second meeting for liquidation purposes within eight (8) months of the initial meeting for liquidation purposes. At this second meeting for liquidation purposes, the general meeting must reconsider whether the Company should continue its operations or go into liquidation.

The board of directors has prepared a new balance sheet for liquidation purposes in accordance with the Companies Act (2005:551) and had it reviewed by the Company's auditor. The balance sheet for liquidation purposes and the auditor's report on the same will be presented at the general meeting.

Item 9.i - The board of directors primarily proposes to continue the Company's operations

The board of directors primarily proposes that the general meeting resolve to continue the Company's operations.

On 18 May 2022, Enorama Pharma announced that the Company had entered into a loan agreement with DS Global for a loan amount of SEK twenty million (20,000,000), with an original maturity date of 28 February 2023 ("Loan Agreement I"). On 21 February 2025, the Company announced that the ongoing annual interest rate had been adjusted from nine (9) percent to ten (10) percent of the outstanding nominal amount. On 23 January 2025, Enorama Pharma announced that the Company had entered into a loan agreement with DS Global for a loan amount of approximately SEK five million (5,000,000), with an annual interest rate of 9 percent ("Loan Agreement II"). On 7 November 2025, Enorama Pharma announced that the Company had entered into a loan agreement with DS Global for a loan facility of USD two million (2,000,000), with an annual interest rate of nine (9) percent on the disbursed loan amount ("Loan Agreement III"). On 18 February 2026, Enorama Pharma announced that the Company had entered into a loan agreement with DS Global under which the Lender makes available a loan facility of USD four million (4,000,000), with an annual interest rate of nine (9) percent on the disbursed loan amount ("Loan Agreement IV"). Loan Agreements I-IV are hereinafter collectively referred to as the "Loan Agreements".

On 13 November 2026, the Company entered into an amendment agreement to the Loan Agreements (the "Amendment Agreement"). Under the Amendment Agreement, the outstanding loans under the Loan Agreements, including interest, shall be repaid with newly issued shares through a directed share issue to the Lender with payment by way of set-off on the maturity date of each loan. The Company is also entitled to repay the outstanding loans under the Loan Agreements in cash prior to their respective maturity dates. The subscription price for each new share that may be issued in such an issue with payment by way of set-off shall be SEK 0.4 per share. For conversion of USD into SEK, SEK 10 shall correspond to USD 1. Through the issue with payment by way of set-off, DS Global may come to hold more than 30 percent of the shares in the Company. The Amendment Agreement results in these debts being reclassified as shareholders' equity in the Company's balance sheet. The Amendment Agreement does not entail any transfer of value from the Company.

On 13 November 2026, the Company entered into the New Loan Agreement with DS Global. Under the New Loan Agreement, USD 2,500,000 is made available to the Company. For further information on the New Loan Agreement, see item 7.

The New Loan Agreement, together with the Amendment Agreement, increases the Company's shareholders' equity to SEK 24,006,297.

The balance sheet for liquidation purposes shows that the Company's equity has been fully restored and the board of directors therefore considers that there is no capital deficiency in the Company. Against this background, the board of directors primarily proposes that the general meeting resolve to continue the Company's operations.

Item 9.ii - The board of directors proposes liquidation as a secondary alternative

The board of directors is required under the Companies Act (2005:551) to prepare a proposal for a resolution on liquidation. The board of directors therefore proposes that, if the general meeting does not resolve in accordance with the board of directors' proposal for continued operations under item 9.i above, the general meeting resolve that the Company shall go into liquidation.

It is proposed that the resolution on liquidation take effect from the date on which the Swedish Companies Registration Office has appointed a liquidator.

The board's preliminary assessment is that distribution of the Company's remaining assets would occur within seven to twelve months after the Swedish Companies Registration Office's decision to appoint a liquidator. The proceeds remaining to be distributed to the shareholders are conservatively estimated to be SEK 0 per share. The board of directors intends to supplement its proposal with a proposed liquidator. 

The board of directors considers that it is only possible to make a rough estimate of the date for distribution and the remaining capital to be distributed at this time.

Available documents

The notice, power of attorney forms and other documents to be made available prior to the general meeting under the Companies Act (2005:551) will be made available to shareholders at the Company's premises at Strandvägen 7A, Stockholm, no later than two weeks before the general meeting. The documents will be sent upon request to shareholders who provide their postal address. The documents will also be available at the general meeting.

Information at the general meeting

Shareholders are informed of their right to request information in accordance with Chapter 7, Section 32 of the Companies Act (2005:551) about circumstances that may affect the assessment of an item on the agenda or the assessment of the Company's financial situation.

Processing of personal data

For information on how your personal data is processed in connection with the general meeting, see:

https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

__________________

Stockholm in November 2026

Enorama Pharma AB (publ)

The board of directors

CONTACT

Enorama Pharma AB (publ)

Amy Walker, acting CEO

info@enorama.se

Strandvägen 7A, 114 51 Stockholm

www.enorama.se

Enorama Pharma AB (publ) is listed on Nasdaq First North Growth Market.

The Company's Certified Adviser is Tapper Partners AB, +46 (0)70 44 010 98, ca@tapperpartners.se.

ABOUT ENORAMA PHARMA

Enorama Pharma's vision is to be a leading global manufacturer and supplier of consumer-friendly, oral nicotine products. The Company intends to expand through product and brand development and by establishing strategically important partnerships. For more information, visit www.enorama.se.

https://news.cision.com/enorama-pharma/r/notice-of-extraordinary-general-meeting-and-second-meeting-for-liquidation-purposes-in-enorama-pharm%2Cc4425442

261117 Styrelsens redogörelse över närståendetransaktioner

261117 Power of attorney

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.